suPARnostic® is prognostic across diseases

suPAR is a universal biomarker. The suPAR level is associated with the presence, severity, and progression of the disease, and in unselected patients, suPAR is one of the strongest prognostic biomarkers available to date.

The suPAR-level is, across diseases, directly linked to morbidity and mortality and can therefore be used to distinguish between non-survivors and survivors.

900+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 4 products:

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

suPARnostic POC+

POC+

Point-of-care finger prick

suPAR is used in clinical routine in 48 hospitals

48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates